Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Mosunetuzumab Approaches EU Approval for Relapsed or Refractory Follicular Lymphoma

April 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval under conditional marketing authorization for mosunetuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 therapies.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2022

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma

April 18th 2022

The addition of bortezomib to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma, according to data from the phase 3 AALL1231 trial.

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn

April 15th 2022

The pending biologics license application and supplemental new drug application seeking the approval of the combination of ublituximab and umbralisib in adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma has been voluntarily withdrawn by TG Therapeutics, Inc.

Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL

April 14th 2022

A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.

Epcoritamab Elicits 63.1% ORR in Relapsed/Refractory Large B-cell Lymphoma

April 14th 2022

Epcoritamab was found to produce an encouraging overall response rate in patients with relapsed or refractory large B-cell lymphoma who previously received CAR T-cell therapy.

First Response Analysis of ALPINE Trial Shows Superior ORR With Zanubrutinib Vs Ibrutinib in CLL

April 11th 2022

Zanubrutinib demonstrated superiority over ibrutinib in terms of overall response rate per independent review committee assessment in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL

April 10th 2022

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Movement of Novel Agents Up Front Is Current Focus in Hematologic Cancers

April 6th 2022

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

FDA Approves Axicabtagene Ciloleucel for Second-Line LBCL

April 1st 2022

The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Lisocabtagene Maraleucel sNDA for Second-Line Relapsed/Refractory LBCL Accepted for Review in Japan

March 26th 2022

The Ministry of Health, Labour, and Welfare has accepted a supplemental new drug application for lisocabtagene maraleucel for the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

FDA Discourages Pursuit of Marketing Authorization for Zandelisib in MZL, Follicular Lymphoma

March 25th 2022

The FDA has discouraged the pursuit of a marketing authorization of the PI3K inhibitor zandelisib in patients with follicular lymphoma or marginal zone lymphoma, citing the need for randomized trial data.

Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

March 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma.

Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

March 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel for use in adult patients with relapsed/refractory follicular lymphoma following 2 lines of systemic treatment.

ZUMA-7 Data Underscore Potential of CAR T-cell Therapy as Second-Line Standard in Relapsed/Refractory LBCL

March 21st 2022

Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.

Dr. Ansell on the Evolving Treatment Landscape in DLBCL

March 15th 2022

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.

Increasing Treatment Pathways Pave the Way for Heartening Future Throughout Hematologic Malignancies

March 9th 2022

Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.

FDA Grants Orphan Drug Designation to Epcoritamab for Follicular Lymphoma

March 8th 2022

The FDA has granted an orphan drug designation to epcoritamab for use as a potential therapeutic option for patients with follicular lymphoma.